VISX loses Nidek patent decision at ITC (International Trade Commisision):
This article was originally published in Clinica
The International Trade Commission (ITC) last week decided that Japanese manufacturer Nidek is not infringing VISX's US patents for refractive eye surgery devices. It ruled that one of VISX's key patents was "invalid and unenforceable" and that Nidek did not infringe the other contested patent. As the ITC is not a court, VISX can appeal the decision to the US Court of Appeals in Washington. VISX shares lost more ground, dropping nearly 8% to $16.56. In recent weeks the Santa Clara, California-based VISX has been forced to reduce its fees and is now facing numerous class action suits, alleging charges of securities fraud and insider dealing (see Clinica No 898, p 12).
You may also be interested in...
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.